Daniel Richard Marshall

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignees: Cybrexa 1, Inc., Cybrexa 2, Inc., Cybrexa 3, Inc.. Active years: 2021-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Richard Marshall. Retrieved from https://idiyas.com/inventor/daniel-richard-marshall-g98uh83g

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 11(Granted Patents)

Company Filing History:

Years Active: 2021-2025

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12427157 - Methods for treatment of diseases involving acidic or hypoxic diseased tissues (2025-09-30),

2. 12410262 - Peptide conjugates of cytotoxins as therapeutics (2025-09-09),

3. 12234212 - Peptide conjugates of microtubule-targeting agents as therapeutics (2025-02-25),

4. 11634508 - Peptide conjugates of cytotoxins as therapeutics (2023-04-25),

5. 11555019 - Peptide conjugates of microtubule-targeting agents as therapeutics (2023-01-17),

6. 10933069 - Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues (2021-03-02),

Title: The Innovations of Daniel Richard Marshall

Introduction

Daniel Richard Marshall is a notable inventor based in New Haven, CT, with a significant contribution to the field of medical treatments. He holds a total of six patents, showcasing his dedication to advancing healthcare solutions. His work primarily focuses on innovative methods for treating diseases that involve acidic or hypoxic diseased tissues.

Latest Patents

Among his latest patents are groundbreaking inventions such as "Methods for treatment of diseases involving acidic or hypoxic diseased tissues" and "Peptide conjugates of cytotoxins as therapeutics." The first patent addresses compounds for treating diseases characterized by acidic or hypoxic conditions, along with pharmaceutical compositions that utilize these compounds. The second patent involves peptide conjugates of cytotoxins, specifically topoisomerase I inhibitors, which are aimed at treating diseases like cancer.

Career Highlights

Daniel has worked with companies such as Cybrexa 1, Inc. and Cybrexa 3, Inc., where he has applied his expertise in developing innovative therapeutic solutions. His career reflects a commitment to improving patient outcomes through scientific advancements.

Collaborations

Throughout his career, Daniel has collaborated with esteemed colleagues, including Robert A. Volkmann and Johanna Csengery. These partnerships have contributed to the success of his inventions and the development of new therapeutic strategies.

Conclusion

Daniel Richard Marshall's contributions to medical innovation are significant, particularly in the treatment of challenging diseases. His patents reflect a deep understanding of complex medical issues and a commitment to finding effective solutions.

Profile summary based on public USPTO records.